We have located links that may give you full text access.
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
Journal of Clinical Oncology 1997 January
PURPOSE: The role of 5-HT3 receptor antagonists in the prevention of chemotherapy-induced delayed emesis is controversial. We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients.
PATIENTS AND METHODS: Three hundred twenty-two patients who had been given > or = 50 mg/m2 of cisplatin were randomly assigned to receive, from days 2 to 4 after chemotherapy, oral ondansetron (8 mg twice daily) or oral metoclopramide (20 mg every 6 hours), both associated with intramuscular dexamethasone (8 mg twice on days 2 and 3, and 4 mg twice on day 4). Patients received the same intravenous prophylaxis for acute emesis: ondansetron 8 mg and dexamethasone 20 mg. Nausea and vomiting were assessed daily until day 6 after chemotherapy.
RESULTS: According to the intention-to-treat principle, 318 patients were assessable. Known prognostic factors were similar in the two treatment groups. Complete protection from delayed vomiting and nausea was achieved by 62.0% and 43.7% of patients treated with ondansetron and by 60.0% and 53.7% of those receiving metoclopramide (no significant differences). Patients who vomited in the first 24 hours achieved the lowest complete protection from delayed emesis. In these patients, ondansetron offered better complete protection from vomiting than metoclopramide (28.6% v 3.8%, P < .05). Both treatments were well tolerated.
CONCLUSION: The two treatments offer similar protection from delayed emesis, although ondansetron plus dexamethasone may be preferred in patients who suffer from acute vomiting. Optimal control of acute emesis is essential to achieve good protection from delayed nausea and vomiting, irrespective of the antiemetic treatment received.
PATIENTS AND METHODS: Three hundred twenty-two patients who had been given > or = 50 mg/m2 of cisplatin were randomly assigned to receive, from days 2 to 4 after chemotherapy, oral ondansetron (8 mg twice daily) or oral metoclopramide (20 mg every 6 hours), both associated with intramuscular dexamethasone (8 mg twice on days 2 and 3, and 4 mg twice on day 4). Patients received the same intravenous prophylaxis for acute emesis: ondansetron 8 mg and dexamethasone 20 mg. Nausea and vomiting were assessed daily until day 6 after chemotherapy.
RESULTS: According to the intention-to-treat principle, 318 patients were assessable. Known prognostic factors were similar in the two treatment groups. Complete protection from delayed vomiting and nausea was achieved by 62.0% and 43.7% of patients treated with ondansetron and by 60.0% and 53.7% of those receiving metoclopramide (no significant differences). Patients who vomited in the first 24 hours achieved the lowest complete protection from delayed emesis. In these patients, ondansetron offered better complete protection from vomiting than metoclopramide (28.6% v 3.8%, P < .05). Both treatments were well tolerated.
CONCLUSION: The two treatments offer similar protection from delayed emesis, although ondansetron plus dexamethasone may be preferred in patients who suffer from acute vomiting. Optimal control of acute emesis is essential to achieve good protection from delayed nausea and vomiting, irrespective of the antiemetic treatment received.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app